Related Experiment Videos
Sequential Adriamycin and CMF in Metastatic Breast Cancer.
Zambetti1, Giacobone, Terenziani
1Istituto Nazionale Tumori, 21033 Milano, Italy.
The Oncologist
|January 1, 1997
Summary
Sequential Adriamycin and CMF chemotherapy shows high effectiveness in metastatic breast cancer patients, offering significant tumor response with manageable side effects. This combination therapy provides a further therapeutic advantage in advanced disease.
Area of Science:
- Oncology
- Medical Oncology
- Clinical Pharmacology
Background:
- Metastatic breast cancer requires effective chemotherapy regimens.
- Sequential drug administration may enhance therapeutic outcomes.
- Evaluating the contribution of individual drug components is crucial.
Purpose of the Study:
- To assess the clinical activity of sequential Adriamycin followed by CMF chemotherapy.
- To determine the therapeutic contribution of each drug regimen in advanced breast cancer.
- To evaluate toxicity and dose intensity of the sequential treatment.
Main Methods:
- A study involving 44 previously untreated advanced breast cancer patients.
- Sequential intravenous Adriamycin (4 cycles) followed by intravenous CMF (4 courses).
- Full conventional doses of both Adriamycin and CMF were administered.
Main Results:
- Adriamycin alone achieved a 75% overall response rate (17% complete remission).
- CMF after Adriamycin increased tumor response in 64% of cases.
- Overall, 78% objective remission (30% complete response) with moderate, short-lasting toxicity.
Conclusions:
- Sequential Adriamycin and CMF is highly effective in untreated metastatic breast cancer.
- The regimen allows for high-dose intensity with moderate toxicity.
- CMF provides a significant additional therapeutic benefit when given after Adriamycin.